Müllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome

Wang, Jeff G.; Nakhuda, Gary S.; Guarnaccia, Michael M.; Sauer, Mark V.; Løbo, Rogerio A.

doi:10.1016/j.ajog.2006.07.046

Cited by 46 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum AMH levels may be related to the severity of the syndrome because they have been observed to be higher in women with insulin-resistant PCOS than in patients with normal insulin sensitivity [38]. According to Wang et al [19], increased plasma AMH concentrations in women with PCOS may be caused by a disruption in folliculogenesis, leading to excessive accumulation of pre-antral and small antral follicles.…”

Section: Discussionmentioning

confidence: 99%

“…Impaired folliculogenesis may result in excess accumulation of pre-antral and small antral follicles, which may ultimately cause the increased AMH levels associated with PCOS [19]. This phenomenon might be the result of an intrinsic abnormality in the ovarian follicles of patients with PCOS, which could contribute to disordered folliculogenesis [20].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Şahmay

Aydın

Öncül

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose We assessed the utility of using anti-Müllerian hormone (AMH) and clinical features of polycystic ovary syndrome (PCOS), polycystic ovarian morphology (PCOM), oligo/amenorrhea (OA), and hyperandrogenism (HA) for diagnosing PCOS, and compared their diagnostic accuracy with those of classical diagnostic systems. Methods A total of 606 females were admitted to a university hospital with menstrual irregularities or symptoms of hyperandrogenism were enrolled in this cross-sectional study. Fasting blood samples were collected. Pelvic and/or abdominal ultrasonography and clinical examination were performed. Patients were evaluated for the presence of PCOS according to conventional diagnostic criteria. The diagnostic performance of using serum AMH levels alone and in various combinations with the clinical features of PCOM, OA, and HA were investigated. Results For the diagnosis of PCOS, the combination of OA and/or HA with AMH showed 83 % sensitivity and 100 % specificity according to the Rotterdam criteria; 83 % sensitivity and 89 % specificity according to the National Institutes of Health (NIH) criteria; and 82 % sensitivity and 93.5 % specificity according to the Androgen Excess Society (AES) criteria. Conclusions The serum AMH level is a useful diagnostic marker for PCOS and is correlated with conventional diagnostic criteria. The combination of AMH level with OA and/ or HA markedly increased the clinical scope for PCOS diagnosis and can be introduced as a possible objective criterion for the diagnosis of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Şahmay

Aydın

Öncül

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Serum AMH levels were found elevated in infertile patients with PCOS, suggesting AMH could present as a biological marker for PCO [15][16][17]. Pigny et al evaluated the diagnostic value of AMH in the diagnosis of PCOS and reported a satisfactory specifi city of 92% and a sensitivity of 67% with a cut-off value of 60 pmol/L [18].…”

Section: Introductionmentioning

confidence: 96%

Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome

Chen

et al. 2010

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…Although these studies do not indicate whether MIS is an intermediate in the action of calcitriol on female reproduction, we speculate that regulation of MIS by calcitriol may play a role. In addition, PCOS has also been associated with high levels of MIS (31)(32)(33)(34). The role of calcitriol and/or the VDR in the overproduction of MIS in PCOS also warrants investigation.…”

Section: Discussionmentioning

confidence: 99%

“…MIS exhibits important actions on steroidogenesis (13, 14), follicle development (15,16,29), ovarian and testicular function (30) and has been linked to polycystic ovarian disease (PCOS) (31)(32)(33)(34). Whether calcitriol and VDR contribute to these activities by induction of MIS is currently unknown and warrants further investigation.…”

Section: Discussionmentioning

confidence: 99%

The Role of Vitamin D Stimulation of Mullerian Inhibiting Substance (MIS) in Prostate Cancer Therapy

Feldman¹

2008

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES ABSTRACTThis grant investigates the potential use of calcitriol regulation of mullerian inhibitory substance (MIS) expression as an incremental therapy for prostate cancer. We have established that calcitriol (1,25-dihydroxyvitamin D3) directly stimulates MIS expression by binding to the vitamin D receptor (VDR) and directing the hormone-receptor complex to bind to a vitamin D regulatory element (VDRE) in the MIS promoter.We have attempted to demonstrate that combination of calcitriol and MIS achieve increased potency to inhibit prostate cancer cell growth compared to either drug alone. However, this has not yet been definitively accomplished although new data are included in this revised report. We further demonstrated the interaction of calcitriol-VDR with other transcription factors, SF-1, SOX-9 and GATA-4, to act together to synergistically increase MIS expression in prostate cancer cells. We believe that some of calcitriol's action to inhibit prostate cancer cell growth are due to stimulation of MIS and this work plans to substantiate this hypothesis and lay the ground work to translate this information to clinical trials in men with prostate cancer. The major focus of the work completed was to document the VDRE in the MIS promoter. This has now been completed and the manuscript published. Preliminary data showing further effects of MIS with and without calcitriol are now included in this report and the findings are confusing.

show abstract

Müllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome

Cited by 46 publications

References 20 publications

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome

The Role of Vitamin D Stimulation of Mullerian Inhibiting Substance (MIS) in Prostate Cancer Therapy

Contact Info

Product

Resources

About